ChloroquineV1, Main, Exploration, bibRecord, 000C42

Circulating Biomarkers From the Phase 1 Trial of Sirolimus and Autophagy Inhibition for Patients With Lymphangioleiomyomatosis.

Identifieur interne : 000C42 ( Main/Exploration ); précédent : 000C41; suivant : 000C43

Circulating Biomarkers From the Phase 1 Trial of Sirolimus and Autophagy Inhibition for Patients With Lymphangioleiomyomatosis.

Auteurs : Anthony M. Lamattina [États-Unis] ; Angelo Taveira-Dasilva [États-Unis] ; Hilary J. Goldberg [États-Unis] ; Shefali Bagwe [États-Unis] ; Ye Cui [États-Unis] ; Ivan O. Rosas [États-Unis] ; Joel Moss [États-Unis] ; Elizabeth P. Henske [États-Unis] ; Souheil El-Chemaly [États-Unis]

Source :

Chest [ 1931-3543 ] ; 2018.

RBID : pubmed:30144422

Descripteurs français

KwdFr :
- Acetyl-coA carboxylase (sang), Adulte, Antienzymes (administration et posologie), Association de médicaments (), Femelle, Fibrinogène (analyse), Humains, Hydroxychloroquine (administration et posologie), Hydroxychloroquine (effets indésirables), Immunosuppresseurs (administration et posologie), Immunosuppresseurs (effets indésirables), Lymphangioléiomyomatose (diagnostic), Lymphangioléiomyomatose (sang), Lymphangioléiomyomatose (traitement médicamenteux), Maladies pulmonaires (diagnostic), Maladies pulmonaires (sang), Maladies pulmonaires (traitement médicamenteux), Marqueurs biologiques (analyse), Marqueurs biologiques (sang), Récepteur-3 au facteur croissance endothéliale vasculaire (sang), Sirolimus (administration et posologie), Sirolimus (effets indésirables), Surveillance pharmacologique (), Tests de la fonction respiratoire ().
MESH :
- administration et posologie : Antienzymes, Hydroxychloroquine, Immunosuppresseurs, Sirolimus.
- analyse : Fibrinogène, Marqueurs biologiques.
- diagnostic : Lymphangioléiomyomatose, Maladies pulmonaires.
- effets indésirables : Hydroxychloroquine, Immunosuppresseurs, Sirolimus.
- sang : Acetyl-coA carboxylase, Lymphangioléiomyomatose, Maladies pulmonaires, Marqueurs biologiques, Récepteur-3 au facteur croissance endothéliale vasculaire.
- traitement médicamenteux : Lymphangioléiomyomatose, Maladies pulmonaires.
- Adulte, Association de médicaments, Femelle, Humains, Surveillance pharmacologique, Tests de la fonction respiratoire.

English descriptors

KwdEn :
- Acetyl-CoA Carboxylase (blood), Adult, Biomarkers (analysis), Biomarkers (blood), Correlation of Data, Drug Monitoring (methods), Drug Therapy, Combination (methods), Enzyme Inhibitors (administration & dosage), Female, Fibrinogen (analysis), Humans, Hydroxychloroquine (administration & dosage), Hydroxychloroquine (adverse effects), Immunosuppressive Agents (administration & dosage), Immunosuppressive Agents (adverse effects), Lung Diseases (blood), Lung Diseases (diagnosis), Lung Diseases (drug therapy), Lymphangioleiomyomatosis (blood), Lymphangioleiomyomatosis (diagnosis), Lymphangioleiomyomatosis (drug therapy), Respiratory Function Tests (methods), Sirolimus (administration & dosage), Sirolimus (adverse effects), Vascular Endothelial Growth Factor Receptor-3 (blood).
MESH :
- chemical , administration & dosage : Enzyme Inhibitors, Hydroxychloroquine, Immunosuppressive Agents, Sirolimus.
- chemical , adverse effects : Hydroxychloroquine, Immunosuppressive Agents, Sirolimus.
- chemical , analysis : Biomarkers, Fibrinogen.
- chemical , blood : Acetyl-CoA Carboxylase, Biomarkers, Vascular Endothelial Growth Factor Receptor-3.
- blood : Lung Diseases, Lymphangioleiomyomatosis.
- diagnosis : Lung Diseases, Lymphangioleiomyomatosis.
- drug therapy : Lung Diseases, Lymphangioleiomyomatosis.
- methods : Drug Monitoring, Drug Therapy, Combination, Respiratory Function Tests.
- Adult, Correlation of Data, Female, Humans.

Abstract

We have previously conducted the Sirolimus and Autophagy Inhibition in LAM (SAIL) trial, a phase 1 dose-escalation study of the combination of sirolimus and hydroxychloroquine in patients with lymphangioleiomyomatosis (LAM). The goal of the present study was to analyze sera from the SAIL trial to identify novel biomarkers that could shed light into disease pathogenesis and response to therapy.

DOI: 10.1016/j.chest.2018.08.1029
PubMed: 30144422

Affiliations:

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Circulating Biomarkers From the Phase 1 Trial of Sirolimus and Autophagy Inhibition for Patients With Lymphangioleiomyomatosis.</title>
<author><name sortKey="Lamattina, Anthony M" sort="Lamattina, Anthony M" uniqKey="Lamattina A" first="Anthony M" last="Lamattina">Anthony M. Lamattina</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Taveira Dasilva, Angelo" sort="Taveira Dasilva, Angelo" uniqKey="Taveira Dasilva A" first="Angelo" last="Taveira-Dasilva">Angelo Taveira-Dasilva</name>
<affiliation wicri:level="2"><nlm:affiliation>Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
<wicri:cityArea>Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Goldberg, Hilary J" sort="Goldberg, Hilary J" uniqKey="Goldberg H" first="Hilary J" last="Goldberg">Hilary J. Goldberg</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Bagwe, Shefali" sort="Bagwe, Shefali" uniqKey="Bagwe S" first="Shefali" last="Bagwe">Shefali Bagwe</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Cui, Ye" sort="Cui, Ye" uniqKey="Cui Y" first="Ye" last="Cui">Ye Cui</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Rosas, Ivan O" sort="Rosas, Ivan O" uniqKey="Rosas I" first="Ivan O" last="Rosas">Ivan O. Rosas</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Moss, Joel" sort="Moss, Joel" uniqKey="Moss J" first="Joel" last="Moss">Joel Moss</name>
<affiliation wicri:level="2"><nlm:affiliation>Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
<wicri:cityArea>Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Henske, Elizabeth P" sort="Henske, Elizabeth P" uniqKey="Henske E" first="Elizabeth P" last="Henske">Elizabeth P. Henske</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="El Chemaly, Souheil" sort="El Chemaly, Souheil" uniqKey="El Chemaly S" first="Souheil" last="El-Chemaly">Souheil El-Chemaly</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. Electronic address: sel-chemaly@partners.org.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston</wicri:cityArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2018">2018</date>
<idno type="RBID">pubmed:30144422</idno>
<idno type="pmid">30144422</idno>
<idno type="doi">10.1016/j.chest.2018.08.1029</idno>
<idno type="wicri:Area/PubMed/Corpus">000089</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000089</idno>
<idno type="wicri:Area/PubMed/Curation">000089</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000089</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000115</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000115</idno>
<idno type="wicri:Area/Ncbi/Merge">000466</idno>
<idno type="wicri:Area/Ncbi/Curation">000466</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000466</idno>
<idno type="wicri:Area/Main/Merge">000C42</idno>
<idno type="wicri:Area/Main/Curation">000C42</idno>
<idno type="wicri:Area/Main/Exploration">000C42</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Circulating Biomarkers From the Phase 1 Trial of Sirolimus and Autophagy Inhibition for Patients With Lymphangioleiomyomatosis.</title>
<author><name sortKey="Lamattina, Anthony M" sort="Lamattina, Anthony M" uniqKey="Lamattina A" first="Anthony M" last="Lamattina">Anthony M. Lamattina</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Taveira Dasilva, Angelo" sort="Taveira Dasilva, Angelo" uniqKey="Taveira Dasilva A" first="Angelo" last="Taveira-Dasilva">Angelo Taveira-Dasilva</name>
<affiliation wicri:level="2"><nlm:affiliation>Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
<wicri:cityArea>Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Goldberg, Hilary J" sort="Goldberg, Hilary J" uniqKey="Goldberg H" first="Hilary J" last="Goldberg">Hilary J. Goldberg</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Bagwe, Shefali" sort="Bagwe, Shefali" uniqKey="Bagwe S" first="Shefali" last="Bagwe">Shefali Bagwe</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Cui, Ye" sort="Cui, Ye" uniqKey="Cui Y" first="Ye" last="Cui">Ye Cui</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Rosas, Ivan O" sort="Rosas, Ivan O" uniqKey="Rosas I" first="Ivan O" last="Rosas">Ivan O. Rosas</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Moss, Joel" sort="Moss, Joel" uniqKey="Moss J" first="Joel" last="Moss">Joel Moss</name>
<affiliation wicri:level="2"><nlm:affiliation>Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
<wicri:cityArea>Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Henske, Elizabeth P" sort="Henske, Elizabeth P" uniqKey="Henske E" first="Elizabeth P" last="Henske">Elizabeth P. Henske</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="El Chemaly, Souheil" sort="El Chemaly, Souheil" uniqKey="El Chemaly S" first="Souheil" last="El-Chemaly">Souheil El-Chemaly</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. Electronic address: sel-chemaly@partners.org.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston</wicri:cityArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Chest</title>
<idno type="eISSN">1931-3543</idno>
<imprint><date when="2018" type="published">2018</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acetyl-CoA Carboxylase (blood)</term>
<term>Adult</term>
<term>Biomarkers (analysis)</term>
<term>Biomarkers (blood)</term>
<term>Correlation of Data</term>
<term>Drug Monitoring (methods)</term>
<term>Drug Therapy, Combination (methods)</term>
<term>Enzyme Inhibitors (administration & dosage)</term>
<term>Female</term>
<term>Fibrinogen (analysis)</term>
<term>Humans</term>
<term>Hydroxychloroquine (administration & dosage)</term>
<term>Hydroxychloroquine (adverse effects)</term>
<term>Immunosuppressive Agents (administration & dosage)</term>
<term>Immunosuppressive Agents (adverse effects)</term>
<term>Lung Diseases (blood)</term>
<term>Lung Diseases (diagnosis)</term>
<term>Lung Diseases (drug therapy)</term>
<term>Lymphangioleiomyomatosis (blood)</term>
<term>Lymphangioleiomyomatosis (diagnosis)</term>
<term>Lymphangioleiomyomatosis (drug therapy)</term>
<term>Respiratory Function Tests (methods)</term>
<term>Sirolimus (administration & dosage)</term>
<term>Sirolimus (adverse effects)</term>
<term>Vascular Endothelial Growth Factor Receptor-3 (blood)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Acetyl-coA carboxylase (sang)</term>
<term>Adulte</term>
<term>Antienzymes (administration et posologie)</term>
<term>Association de médicaments ()</term>
<term>Femelle</term>
<term>Fibrinogène (analyse)</term>
<term>Humains</term>
<term>Hydroxychloroquine (administration et posologie)</term>
<term>Hydroxychloroquine (effets indésirables)</term>
<term>Immunosuppresseurs (administration et posologie)</term>
<term>Immunosuppresseurs (effets indésirables)</term>
<term>Lymphangioléiomyomatose (diagnostic)</term>
<term>Lymphangioléiomyomatose (sang)</term>
<term>Lymphangioléiomyomatose (traitement médicamenteux)</term>
<term>Maladies pulmonaires (diagnostic)</term>
<term>Maladies pulmonaires (sang)</term>
<term>Maladies pulmonaires (traitement médicamenteux)</term>
<term>Marqueurs biologiques (analyse)</term>
<term>Marqueurs biologiques (sang)</term>
<term>Récepteur-3 au facteur croissance endothéliale vasculaire (sang)</term>
<term>Sirolimus (administration et posologie)</term>
<term>Sirolimus (effets indésirables)</term>
<term>Surveillance pharmacologique ()</term>
<term>Tests de la fonction respiratoire ()</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Enzyme Inhibitors</term>
<term>Hydroxychloroquine</term>
<term>Immunosuppressive Agents</term>
<term>Sirolimus</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Hydroxychloroquine</term>
<term>Immunosuppressive Agents</term>
<term>Sirolimus</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Biomarkers</term>
<term>Fibrinogen</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Acetyl-CoA Carboxylase</term>
<term>Biomarkers</term>
<term>Vascular Endothelial Growth Factor Receptor-3</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Antienzymes</term>
<term>Hydroxychloroquine</term>
<term>Immunosuppresseurs</term>
<term>Sirolimus</term>
</keywords>
<keywords scheme="MESH" qualifier="analyse" xml:lang="fr"><term>Fibrinogène</term>
<term>Marqueurs biologiques</term>
</keywords>
<keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Lung Diseases</term>
<term>Lymphangioleiomyomatosis</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Lung Diseases</term>
<term>Lymphangioleiomyomatosis</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Lymphangioléiomyomatose</term>
<term>Maladies pulmonaires</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Lung Diseases</term>
<term>Lymphangioleiomyomatosis</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Hydroxychloroquine</term>
<term>Immunosuppresseurs</term>
<term>Sirolimus</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Drug Monitoring</term>
<term>Drug Therapy, Combination</term>
<term>Respiratory Function Tests</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Acetyl-coA carboxylase</term>
<term>Lymphangioléiomyomatose</term>
<term>Maladies pulmonaires</term>
<term>Marqueurs biologiques</term>
<term>Récepteur-3 au facteur croissance endothéliale vasculaire</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Lymphangioléiomyomatose</term>
<term>Maladies pulmonaires</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Correlation of Data</term>
<term>Female</term>
<term>Humans</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adulte</term>
<term>Association de médicaments</term>
<term>Femelle</term>
<term>Humains</term>
<term>Surveillance pharmacologique</term>
<term>Tests de la fonction respiratoire</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We have previously conducted the Sirolimus and Autophagy Inhibition in LAM (SAIL) trial, a phase 1 dose-escalation study of the combination of sirolimus and hydroxychloroquine in patients with lymphangioleiomyomatosis (LAM). The goal of the present study was to analyze sera from the SAIL trial to identify novel biomarkers that could shed light into disease pathogenesis and response to therapy.</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Maryland</li>
<li>Massachusetts</li>
</region>
</list>
<tree><country name="États-Unis"><region name="Massachusetts"><name sortKey="Lamattina, Anthony M" sort="Lamattina, Anthony M" uniqKey="Lamattina A" first="Anthony M" last="Lamattina">Anthony M. Lamattina</name>
</region>
<name sortKey="Bagwe, Shefali" sort="Bagwe, Shefali" uniqKey="Bagwe S" first="Shefali" last="Bagwe">Shefali Bagwe</name>
<name sortKey="Cui, Ye" sort="Cui, Ye" uniqKey="Cui Y" first="Ye" last="Cui">Ye Cui</name>
<name sortKey="El Chemaly, Souheil" sort="El Chemaly, Souheil" uniqKey="El Chemaly S" first="Souheil" last="El-Chemaly">Souheil El-Chemaly</name>
<name sortKey="Goldberg, Hilary J" sort="Goldberg, Hilary J" uniqKey="Goldberg H" first="Hilary J" last="Goldberg">Hilary J. Goldberg</name>
<name sortKey="Henske, Elizabeth P" sort="Henske, Elizabeth P" uniqKey="Henske E" first="Elizabeth P" last="Henske">Elizabeth P. Henske</name>
<name sortKey="Moss, Joel" sort="Moss, Joel" uniqKey="Moss J" first="Joel" last="Moss">Joel Moss</name>
<name sortKey="Rosas, Ivan O" sort="Rosas, Ivan O" uniqKey="Rosas I" first="Ivan O" last="Rosas">Ivan O. Rosas</name>
<name sortKey="Taveira Dasilva, Angelo" sort="Taveira Dasilva, Angelo" uniqKey="Taveira Dasilva A" first="Angelo" last="Taveira-Dasilva">Angelo Taveira-Dasilva</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C42 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000C42 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    ChloroquineV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:30144422
   |texte=   Circulating Biomarkers From the Phase 1 Trial of Sirolimus and Autophagy Inhibition for Patients With Lymphangioleiomyomatosis.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:30144422" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a ChloroquineV1

This area was generated with Dilib version V0.6.33.
Data generation: Wed Mar 25 22:43:59 2020. Site generation: Sun Jan 31 12:44:45 2021

Serveur d'exploration Chloroquine

Circulating Biomarkers From the Phase 1 Trial of Sirolimus and Autophagy Inhibition for Patients With Lymphangioleiomyomatosis.

Circulating Biomarkers From the Phase 1 Trial of Sirolimus and Autophagy Inhibition for Patients With Lymphangioleiomyomatosis.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	Serveur d'exploration Chloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.